Delivery methods for drugs used in the treatment of overactive bladder

References

• Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57:1044–1050.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. discussion 14–5
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–336.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–1087.
   PubMed Web of Science ®Google Scholar
• Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol. 2004;11:2278–2284.
   PubMedGoogle Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.
   PubMed Web of Science ®Google Scholar
• Tikkinen KA, Tammela TL, Rissanen AM, et al. Is the prevalence of overactive bladder overestimated? A population-based study in Finland. PLoS One. 2007;2:e195.
   PubMed Web of Science ®Google Scholar
• Melville JL, Delaney K, Newton K, et al. Incontinence severity and major depression in incontinent women. Obstet Gynecol. 2005;106:585–592.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59:1465–1470.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–463.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193:1572–1580.
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276–1282.
   PubMed Web of Science ®Google Scholar
• Aaltonen L, Allonen H, Iisalo E, et al. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol Toxicol (Copenh). 1984;55:100–103.
   PubMedGoogle Scholar
• Lindeke B, Hallstrom G, Johansson C, et al. Metabolism of oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed Mass Spectrom. 1981;8:506–513.
   PubMedGoogle Scholar
• Corcos J. Synthesis of practical approaches to overactive bladder. In: Corcos J, MacDiarmid SA, Heesakkers J, editors. Overactive bladder. Chichester: Wiley; 2015. p. 233–237.
   Google Scholar
• Katzung B, P A. Autonomic drugs. In: Medical M-H, editor. Basic & clinical pharmacology. 12th ed. New York (NY): Lange; 2012.
   Google Scholar
• Bardal S, W J, Martin D. Anticholinergics: bladder. Applied Pharmacology. St. Louis (MO): Elsevier/Saunders; 2011. p. 413–414.
   Google Scholar
• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19:380–394.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414–421.
   PubMed Web of Science ®Google Scholar
• Griebling TL, Kraus SR, Richter HE, et al. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract. 2009;63:1198–1204.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Rackley R, Nitti VW, et al. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008;72:488–493.
   PubMed Web of Science ®Google Scholar
• Varadharajan S, Jumadilova Z, Girase P, et al. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005;11:S140–9.
   Web of Science ®Google Scholar
• Peeker R, Samsioe G, Kowalski J, et al. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol. 2010;44:138–146.
   PubMed Web of Science ®Google Scholar
• Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract. 2006;60:752–758.
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000;95:718–721.
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 1999;161:1809–1812.
   PubMed Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14:291–301.
   PubMed Web of Science ®Google Scholar
• Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin. 2007;23:2697–2704.
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98:1025–1032.
   PubMed Web of Science ®Google Scholar
• Lee KS, Lee HW, Choo MS, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’. BJU Int. 2010;105:1565–1570.
   PubMed Web of Science ®Google Scholar
• Gotoh M, Yokoyama O, Nishizawa O. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol. 2011;18:365–373.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Lee DG, Lee SW, et al. Efficacy and safety of propiverine in children with overactive bladder. Korean J Urol. 2012;53:275–279.
   PubMedGoogle Scholar
• Homma Y, Yamaguchi O. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009;16:499–506.
   PubMed Web of Science ®Google Scholar
• Masumori N, Miyamoto S, Tsukamoto T, et al. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. Adv Urol. 2011;2011:714978.
   PubMedGoogle Scholar
• Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105:58–66.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011;107:1432–1440.
   PubMed Web of Science ®Google Scholar
• Huang W, Zong H, Zhou X, et al. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47:457–464.
   PubMed Web of Science ®Google Scholar
• Park C, Park J, Choo MS, et al. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. Int J Clin Pract. 2014;68:188–196.
   PubMed Web of Science ®Google Scholar
• Lee KS, Park B, Kim JH, et al. A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder. Int J Clin Pract. 2013;67:1317–1326.
   PubMed Web of Science ®Google Scholar
• Matsukawa Y, Takai S, Funahashi Y, et al. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology. 2015;85:786–790.
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755–765.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014;21:960–967.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113:951–960.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34:685–692.
   PubMed Web of Science ®Google Scholar
• Chapple C, Khullar V, Nitti VW, et al. Efficacy of the beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015;67:11–14.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015;116:612–622.
   PubMed Web of Science ®Google Scholar
• Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43:666–675.
   PubMed Web of Science ®Google Scholar
• Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98:1310–1314.
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62:834–840.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Martin N, Nitti V. Selective beta(3)-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190:1173–1180.
   PubMed Web of Science ®Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323:202–209.
   PubMed Web of Science ®Google Scholar
• Igawa Y, Michel MC. Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:177–183.
   PubMed Web of Science ®Google Scholar
• Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol. 1998;160:892–896.
   PubMed Web of Science ®Google Scholar
• De Wachter S, Wyndaele JJ. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol. 2003;169:1892–1895.
   PubMed Web of Science ®Google Scholar
• Krause P, Fuhr U, Schnitker J, et al. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol. 2013;190:1791–1797.
   PubMed Web of Science ®Google Scholar
• Oki T, Kimura R, Saito M, et al. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004;172:2059–2064.
   PubMed Web of Science ®Google Scholar
• Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia. 1991;29:84–90.
   PubMedGoogle Scholar
• Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol. 2002;36:18–24.
   PubMed Web of Science ®Google Scholar
• Saito M, Tabuchi F, Otsubo K, et al. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn. 2000;19:683–688.
   PubMed Web of Science ®Google Scholar
• Ersoz M, Yildiz N, Akyuz M, et al. Efficacy of combined oral-intravesical oxybutynin hydrochloride treatment for patients with overactive detrusors and indwelling urethral catheters. Rehabil Nurs. 2010;35:80–86.
   PubMed Web of Science ®Google Scholar
• Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol. 2002;45:205–217.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014;23:751–757.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Z, Liu C, et al. Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. Drug Dev Ind Pharm. 2012;38:1008–1014.
   PubMed Web of Science ®Google Scholar
• Sahai A, Mallina R, Dowson C, et al. Evolution of transdermal oxybutynin in the treatment of overactive bladder. Int J Clin Pract. 2008;62:167–170.
   PubMed Web of Science ®Google Scholar
• Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res. 2003;20:103–109.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580–586.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–242.
   PubMed Web of Science ®Google Scholar
• Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011;107:70–76.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol. 2005;23:263–270.
   PubMed Web of Science ®Google Scholar
• Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007;99:836–844.
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140–145.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK, Sand PK, et al. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011;31:559–571.
   PubMed Web of Science ®Google Scholar
• Caramelli K, S D, Volinn W. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system. J Urol. 2008;179:513–514.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009;181:1764–1772.
   PubMed Web of Science ®Google Scholar
• Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012;206:168 e1–6.
   PubMed Web of Science ®Google Scholar
• Levin RM, Whitbeck C, Borow A, et al. Effectiveness of vaginally administered oxybutynin on rabbit bladder function. Urology. 2003;61:1273–1277.
   PubMed Web of Science ®Google Scholar
• Chou EC, Whitbeck C, Borow A, et al. Inhibition of hyperreflexia by vaginally administered oxybutynin: a novel rabbit model. J Urol. 2004;171:958–962.
   PubMed Web of Science ®Google Scholar
• M G, R K, Dasen S, et al. A phase 2 study evaluating the safety and efficacy of two doses of a monthly oxybutynin vaginal ring in women with symptoms of overactive bladder. Int Urogynecol J. 2001;22:138–139.
   Google Scholar
• Das AK, M J. The safety, local tolerability, pharmacokinetics, and risk/benefit of oxybutynin transvaginal rings (TVR) in women with a history of overactive bladder. Synopsis -FEI Ph 1 PK Study FEI Technologies, Inc report. 2001.
   Google Scholar
• Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9:100–102.
   PubMedGoogle Scholar
• Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J. 2013;24:595–604.
   PubMed Web of Science ®Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55:33–46. discussion 50.
   PubMed Web of Science ®Google Scholar